To evaluate the effect of modified wheelchair arm-support to mitigate hemiplegic shoulder pain and reduce pain frequency in stroke patients. A single-blind randomized controlled trial using computer-generated simple randomization. Participants recruited from inpatients at the Guangdong Provincial Hospital of Chinese Medicine. A total of 120 patients with stroke were divided into two groups. All subjects underwent basic rehabilitation training and wheelchair assistance with eight weeks follow-up period. Patients in the treatment group additionally received modified wheelchair arm-support for at least 60 minutes a day, six days a week, for four weeks. Primary outcome was measured by the Visual Analogue Pain Scale or Numeric Pain Rating Scale. Secondary outcome was measured using the Upper Extremity Fugl-Meyer Assessment scale, Modified Barthel Index and Quality of Life Index. Measurements were made at 4 weeks and 12 weeks, following the intervention. Patients age from 21 to 83 years (mean ± SD = 62.41 ± 12.26). The average duration of disease was 1.9 ± 1.3 months. At four weeks, the median of pain intensity was higher in the control group (median, interquartile range = 3, 5.75 vs. 2, 3.75; P = 0.059). At 12 weeks, the median of pain intensity was higher in the control group (median, interquartile range = 3, 5.00 vs. 0, 1.00; P < 0.001). At 12 weeks, patients with shoulder pain were higher in the control group (6 vs. 1; P < 0.05). Using the modified wheelchair arm-support could lead to the mitigation of hemiplegic shoulder pain and reduction in pain incidence in stroke patients. It may also improve the patients’ quality of life.
Post-stroke shoulder-hand syndrome (SHS) is a common complication after stroke. To date, there is still a lack of consistently effective and good patient compliance methods for SHS. Fifty patients with SHS were included in this study. Patients in the control group received rehabilitation training (RT) for 2 weeks; each session was 30 min, 1 time per day, and 5 times per week. Patients in the observation group were additionally given Bo's abdominal acupuncture (BAA) with the same frequency and duration. The primary outcome was the change value in the VAS score from baseline to 2 weeks. The secondary outcomes measured were motor function of the upper limb, shoulder range of motion, ADL, and swelling volume. Compared with baseline values, the mean VAS score at 2 weeks was reduced by 3.68 in the observation group and by 1.92 in the control group, with a difference between the two groups of 1.84 (P < 0.001); the mean MBI score at 2 weeks increased by 10.44 in the observation group and by 4.79 in the control group, with a difference between the two groups of 5.84 (P = 0.032); the mean swelling volume at 2 weeks decreased by 9.64 in the observation group and by 3.29 in the control group, with a difference between the two groups of 6.48 (P < 0.001). BAA-related adverse events were not found during the study. BAA combined with RT is superior to RT alone in improving shoulder pain, swelling, and ADL in post-stroke SHS patients. ChiCTR2100045464 (www.chictr.org.cn).
Objective: To investigate the neuroprotection effect of the combination of astragalus membranaceus and ligustrazine on thrombolysis after ischemic stroke and explore its mechanism basing on the Notch signaling pathway. Materials and methods: Focal cerebral ischemia models were induced by autologous thrombus of middle cerebral artery occlusion (MCAO). Male Sprague-Dawley (SD) rats were randomly divided into 3 experimental groups: MCAO group, Thrombolysis by rt-PA group, Thrombolysis+combination treatment group. Rt-PA (5mg/kg) was administrated 3h after MCAO onset and combination treatment of astragalus membranaceus and ligustrazine (0.1-0.2ml/100g) was administrated immediately after thrombolysis. Rats were sacrificed 3h and 24h after thrombolysis. The expression levels of Notch1, HES1 were detected by Western blotting (WB) and quantitative real-time PCR (RT-PCR). Results: Compared with those results of MCAO group and Thrombolysis by rt-PA group, Thrombolysis+ combination treatment group markedly decreased the expression of Notch1, HES1, in protein and mRNA, 3h after thrombolysis (P<;0.01, P<;0.01). And the trend of decrease was more pronounced at 24h (P<;0.01, P<;0.01). Conclusions: The findings demonstrate that the combination of astragalus membranaceus and ligustrazine might promote neuroprotection effect through down-regulation the activation of Notch1/HES1 signaling pathways.